The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
Randall J. Bateman(Washington University in St. Louis), Chengjie Xiong(Guangzhou Institutes of Biomedicine and Health), Kathleen Fanning(Washington University in St. Louis), Scott Berry(Queen's University), Anne M. Fagan(Washington University in St. Louis), Cynthia Duggan(Rockefeller University), Anna Santacruz(Washington University in St. Louis), Lon S. Schneider(University of Southern California), Tammie L.S. Benzinger(Washington University in St. Louis), Eric McDade(University of Pittsburgh), Susan Mills(Ollscoil na Gaillimhe – University of Galway), Martin R. Farlow(MRC Laboratory of Molecular Biology), Guoqiao Wang(Washington University in St. Louis), Melanie Quintana(Berry & Associates (United States)), Katrina L. Paumier(Washington University in St. Louis), David B. Clifford(Washington University in St. Louis), Jason Hassenstab(Washington University in St. Louis), Stephen Salloway(Providence College)
Cited by 303
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k